Skip to content
Radio Logo
PodcastsNatural SciencesMendelspod Podcast

Mendelspod Podcast

Theral Timpson
Latest episode

583 episodes

  • Mendelspod Podcast

    When to Begin Developing the Companion Diagnostic? With Gulzar Sandhu, Agilent Technologies

    19/11/2026 | 27 mins.
    When should a pharma company begin developing the diagnostic that will identify which patients benefit from a new drug? Early enough to avoid costly delays, but not so early that the company limits the possibilities for the drug.
    Gulzar Sandhu, Head of Business Development for Biopharma Assay Development at Agilent Technologies, joins us to explore this delicate balance. Companion diagnostics can dramatically improve clinical trial outcomes by identifying patients most likely to respond to a therapy. But developing these tests requires significant investment. Still, to delay can be costly and endanger the entire drug program.
    Drawing on Agilent’s experience with PD-L1 assays, Sandhu describes how the companion diagnostic business is evolving. Pharmaceutical companies are increasingly pursuing multiple indications simultaneously, driving up diagnostic development costs. Agilent has set up a lab called Biopharma CDx Services Lab or BCSL with a staged development model that allows companies to begin clinical testing with substantially less investment while preserving a pathway toward full regulatory approval.
    Looking ahead, Sandhu discusses the growing importance of antibody-drug conjugates, digital pathology, and multi-omics in identifying new patient populations. First, Sandhu says that the technology Agilent uses for testing comes directly from the biology of the drug candidate. Second, he reminds us that technological sophistication isn’t everything. A diagnostic must ultimately be accessible to patients around the world. “IHC is accessible in every nook and cranny of the world,” he says, explaining why this established technology remains so important even as newer approaches such as DNA and protein sequencing emerge.
    The conversation offers a revealing look at how drug development and diagnostic development are becoming increasingly intertwined. Getting that relationship right is central to the future of precision medicine.
    D0155698_1.00


    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
  • Mendelspod Podcast

    The $60 Genome, Virtual Cell Modeling and the Future of Biology, with Gilad Almogy, Ultima Genomics

    12/11/2026 | 6 mins.
    This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

    Can we scale our way to a better understanding of biology?
    When we first had the CEO and founder of Ultima Genomics on the show, the company had just emerged from stealth with an ambitious vision. Coming from the semiconductor industry, Gilad Almogy believed that dramatically reducing the cost of DNA sequencing would enable scientists to study biology at an entirely new scale. And that scale would lead to discoveries we couldn’t yet imagine. A few years later, Ultima has announced the $60 genome and is partnering on some of the largest biological research projects ever undertaken.
    Almogy returns today to discuss the company’s progress and how the arrival of AI has accelerated his original vision. Ultima’s new UG200 platform offers greater throughput, improved coverage and paired-end sequencing, expanding the technology’s applications beyond large-scale counting experiments into whole-genome sequencing and clinical testing.
    Among the company’s major collaborations are the Billion Cells Project with the Chan Zuckerberg Initiative and the Arc Virtual Cell Atlas. Both aim to generate enormous datasets of cellular responses to perturbations, providing training data for AI models that could eventually predict how cells behave. Almogy argues that biology may be too complex to model using traditional mathematical approaches alone. As he puts it, “A cell is a video. It’s not an image.” He believes AI could do for biology what mathematics did for physics.
    The conversation also explores Ultima’s population genomics partnerships with Mayo Clinic and Singapore. Mayo’s Precure Initiative aims to combine whole-genome sequencing and proteomics with electronic health records from a million patients, while Singapore’s national precision medicine program will test how genomic information can improve clinical care. Almogy sees these efforts as complementary to the virtual cell projects, approaching biology from the level of entire populations rather than individual cells.
    Finally, Almogy discusses the growing importance of longitudinal sequencing and liquid biopsy. Ultima’s ppmSeq technology, designed to detect variants at frequencies as low as one part per million, could help enable more sensitive MRD testing in cancer treatment.
    The future of biology will require models at several scales, from individual cells to entire populations, along with dynamic models that follow how human health changes over time. These models will need vast amounts of data. The hope is that AI will find insights in this data that we haven’t yet imagined, ultimately making biology more predictive and leading to earlier disease detection and better medicine.
  • Mendelspod Podcast

    Precision Oncology 2.0: From Tumor Profiling to Continuous Monitoring with Jerry Radich, Fred Hutch

    05/11/2026 | 24 mins.
    Precision oncology is entering a new phase. Rather than simply profiling a tumor and matching it to a drug, physicians are increasingly able to follow a patient’s cancer over time, measuring treatment response, detecting residual disease, and adjusting therapy as the disease evolves.
    Jerry Radich of Fred Hutch Cancer Center has been at the forefront of this evolution. His pioneering work in chronic myeloid leukemia (CML) helped establish molecular monitoring as a critical part of cancer care and prefigured the rise we see in MRD testing today. Some CML patients can even discontinue treatment after achieving a sustained deep molecular response. Radich discusses how this remarkable success has become a model for other blood cancers.
    He’s now helping lead myeloMATCH, a national precision oncology initiative that brings together clinical trial groups across North America. With some 350 participating sites and molecular results typically available in less than 48 hours, the program is matching patients with acute myeloid leukemia to clinical trials based on their cancer’s genetic profile. Radich sees an opportunity not only to personalize treatment but to accelerate drug development by using molecular response as an earlier measure of efficacy.
    We also explore the limits of molecular profiling, the emerging role of the immune system, and why increasingly sensitive tests may transform how we understand cancer. Looking ahead, Radich imagines a future in which patients could monitor their disease burden almost continuously, perhaps even through wearable or implantable devices.
    Radich is co-chairing the upcoming APOAPE conference in Seattle on January 15, bringing oncologists and pathologists together to connect advances in molecular diagnostics with real-world treatment decisions. The conference is free for healthcare professionals.
    Learn more about the APOAPE conference


    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
  • Mendelspod Podcast

    The UK’s Next Big Bet on Precision Medicine: Our Future Health with CEO Raghib Ali

    03/11/2026 | 38 mins.
    In the US, we have the All of Us Research Program. In the UK, they have Our Future Health, an ambitious new population health research program that aims to make healthcare more preventive than reactive. Launched just four years ago, it has already recruited nearly three million volunteers toward a goal of five million, making it one of the world’s largest health research initiatives.
    Today we’re joined by Raghib Ali, CEO and Principal Investigator of Our Future Health, to discuss how the program builds on the success of UK Biobank while pursuing a different goal. Rather than simply studying the causes of disease, Our Future Health aims to establish the evidence needed to move healthcare from diagnosis and treatment toward prediction and prevention.
    Ali discusses the program’s plans to combine polygenic risk scores with clinical and lifestyle data to develop integrated disease risk scores. A new clinical trials platform will test whether personalized prevention actually improves outcomes. The ultimate ambition is to bring successful approaches into routine NHS care.
    Perhaps most encouraging is the public response. More than a million participants have come from historically underrepresented groups, raising the possibility that precision medicine could help reduce health inequalities rather than widen them.
    As Ali puts it, the goal is to move from a national sickness service to a true national health service.


    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
  • Mendelspod Podcast

    From the Archives: The Dark Genome Is Coming Into Focus with Sudhakaran Prabakaran

    27/10/2026 | 37 mins.
    In recent months on Mendelspod, we’ve explored how new sequencing and proteomics technologies are revealing biology in regions of the genome (and proteome) that have long escaped our attention. From repeat expansion disorders to new approaches in cancer diagnostics, the dark genome is increasingly becoming clinically relevant.
    Today we’re revisiting a conversation from earlier in the year that asks an even bigger question. What if much of this unexplored genomic territory is not simply functional, but a reservoir of evolutionary possibility?
    Last March, we talked with Sudhakaran Prabakaran, computational biologist at Northeastern University, founder of NonExomics, and author of Eclipsed Horizons: Unveiling the Dark Genome.
    Drawing on his lab’s work cataloging more than 250,000 non-canonical proteins, Prabakaran argued that regions outside traditional gene definitions may be continually generating new proteins with implications for adaptation, evolution, and disease.
    From rapidly diversifying cichlid fishes to human accelerated regions (HARs) of the human genome linked to schizophrenia, Sudhakaran makes the case that protein birth and death is continuous, cheap, and exploratory. In his framing, the “dark genome” functions less like debris and more like a flexible evolutionary sandbox. His company, NonExomics, is also exploring how these previously overlooked proteins might become biomarkers for cancer and other diseases.
    As our recent interviews have demonstrated, we’re entering a new era of genomic discovery. Prabakaran challenges us to think about just how much biology remains to be found.


    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe
More Natural Sciences podcasts
About Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine. www.mendelspod.com
Podcast website

Listen to Mendelspod Podcast, The Science of Everything Podcast and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
Mendelspod Podcast: Podcasts in Family